Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice

Purpose Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer’s disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and...

Descripción completa

Detalles Bibliográficos
Autores: Echeveste, B. (Beatriz)|||/items/b19fc9ee-f0ed-4738-b796-38fdf7be068e, Prieto-Azcárate, E. (Elena)|||/items/98983a2a-3ce1-471b-8174-68cd47fc9fcb, Guillén-Valderrama, E.F. (Edgar Fernando)|||/items/49baa399-7bfa-4ee4-ae2e-de817a075b4f, Jiménez-Huete, A. (Adolfo)|||/items/835a290a-50ce-4e91-bd76-42946f89f501, Montoya-Murillo, G. (Genoveva)|||/items/760874d6-2e69-478b-a06d-df3421388bdc, Villino-Rodríguez, R.Á. (Rafael Ángel)|||/items/21c8cd1b-0bcd-4181-9a14-3052d2fe478c, Riverol-Fernández, M. (Mario)|||/items/d2bcd472-bb2a-4e9c-b381-00f4e363b24d, Arbizu, J. (Javier)|||/items/41665d76-74c1-4652-acb9-a98cba4ddd0b
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/120959
Acceso en línea:https://hdl.handle.net/10171/120959
Access Level:acceso abierto
Palabra clave:Amnestic mild cognitive impairment (aMCI)
Alzheimer’s disease (AD)
Short-term conversion
AmyloidPET
FDG-PET
id ES_671158bc4e2e4591a4db3808628cc7e4
oai_identifier_str oai:dadun.unav.edu:10171/120959
network_acronym_str ES
network_name_str España
repository_id_str
spelling Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practiceEcheveste, B. (Beatriz)|||/items/b19fc9ee-f0ed-4738-b796-38fdf7be068ePrieto-Azcárate, E. (Elena)|||/items/98983a2a-3ce1-471b-8174-68cd47fc9fcbGuillén-Valderrama, E.F. (Edgar Fernando)|||/items/49baa399-7bfa-4ee4-ae2e-de817a075b4fJiménez-Huete, A. (Adolfo)|||/items/835a290a-50ce-4e91-bd76-42946f89f501Montoya-Murillo, G. (Genoveva)|||/items/760874d6-2e69-478b-a06d-df3421388bdcVillino-Rodríguez, R.Á. (Rafael Ángel)|||/items/21c8cd1b-0bcd-4181-9a14-3052d2fe478cRiverol-Fernández, M. (Mario)|||/items/d2bcd472-bb2a-4e9c-b381-00f4e363b24dArbizu, J. (Javier)|||/items/41665d76-74c1-4652-acb9-a98cba4ddd0bAmnestic mild cognitive impairment (aMCI)Alzheimer’s disease (AD)Short-term conversionAmyloidPETFDG-PETPurpose Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer’s disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and FDG-PET in determining progression to AD among patients with aMCI. Methods This study recruited 145 patients with aMCI from October 2013 to March 2021. The patients were classified into four groups based on whether Amyloid-PET (A) and FDG-PET (N) were positive (+) or negative (-). The patients were then clinically followed to establish progression to dementia due to AD. Results Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased. The conversion from aMCI to AD had a global mean time of 39.95 months. However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54–81] vs. 32.59 months [CI 20.56–40.74] months). Taking both tests together, the time to conversion was faster in A+/N+versus A+/N- patients (27.79 [CI 20.40–33.21] vs. 37.38 [CI 20.73–48.26] months). Conclusions Among patients with aMCI, those with a positive Amyloid-PET and an AD pattern on FDG-PET progressed to dementia significantly earlier versus those with a positive Amyloid-PET only. Using both biomarkers during the initial diagnosis enhances the prediction of short-term conversion. Clinical trial number Not applicable. It is not a clinical trialDadun. Depósito Académico Digital Universidad de Navarra20252025-01-0120252025-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/120959reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1209592026-06-21T12:47:57Z
dc.title.none.fl_str_mv Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
title Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
spellingShingle Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
Echeveste, B. (Beatriz)|||/items/b19fc9ee-f0ed-4738-b796-38fdf7be068e
Amnestic mild cognitive impairment (aMCI)
Alzheimer’s disease (AD)
Short-term conversion
AmyloidPET
FDG-PET
title_short Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
title_full Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
title_fullStr Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
title_full_unstemmed Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
title_sort Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
dc.creator.none.fl_str_mv Echeveste, B. (Beatriz)|||/items/b19fc9ee-f0ed-4738-b796-38fdf7be068e
Prieto-Azcárate, E. (Elena)|||/items/98983a2a-3ce1-471b-8174-68cd47fc9fcb
Guillén-Valderrama, E.F. (Edgar Fernando)|||/items/49baa399-7bfa-4ee4-ae2e-de817a075b4f
Jiménez-Huete, A. (Adolfo)|||/items/835a290a-50ce-4e91-bd76-42946f89f501
Montoya-Murillo, G. (Genoveva)|||/items/760874d6-2e69-478b-a06d-df3421388bdc
Villino-Rodríguez, R.Á. (Rafael Ángel)|||/items/21c8cd1b-0bcd-4181-9a14-3052d2fe478c
Riverol-Fernández, M. (Mario)|||/items/d2bcd472-bb2a-4e9c-b381-00f4e363b24d
Arbizu, J. (Javier)|||/items/41665d76-74c1-4652-acb9-a98cba4ddd0b
author Echeveste, B. (Beatriz)|||/items/b19fc9ee-f0ed-4738-b796-38fdf7be068e
author_facet Echeveste, B. (Beatriz)|||/items/b19fc9ee-f0ed-4738-b796-38fdf7be068e
Prieto-Azcárate, E. (Elena)|||/items/98983a2a-3ce1-471b-8174-68cd47fc9fcb
Guillén-Valderrama, E.F. (Edgar Fernando)|||/items/49baa399-7bfa-4ee4-ae2e-de817a075b4f
Jiménez-Huete, A. (Adolfo)|||/items/835a290a-50ce-4e91-bd76-42946f89f501
Montoya-Murillo, G. (Genoveva)|||/items/760874d6-2e69-478b-a06d-df3421388bdc
Villino-Rodríguez, R.Á. (Rafael Ángel)|||/items/21c8cd1b-0bcd-4181-9a14-3052d2fe478c
Riverol-Fernández, M. (Mario)|||/items/d2bcd472-bb2a-4e9c-b381-00f4e363b24d
Arbizu, J. (Javier)|||/items/41665d76-74c1-4652-acb9-a98cba4ddd0b
author_role author
author2 Prieto-Azcárate, E. (Elena)|||/items/98983a2a-3ce1-471b-8174-68cd47fc9fcb
Guillén-Valderrama, E.F. (Edgar Fernando)|||/items/49baa399-7bfa-4ee4-ae2e-de817a075b4f
Jiménez-Huete, A. (Adolfo)|||/items/835a290a-50ce-4e91-bd76-42946f89f501
Montoya-Murillo, G. (Genoveva)|||/items/760874d6-2e69-478b-a06d-df3421388bdc
Villino-Rodríguez, R.Á. (Rafael Ángel)|||/items/21c8cd1b-0bcd-4181-9a14-3052d2fe478c
Riverol-Fernández, M. (Mario)|||/items/d2bcd472-bb2a-4e9c-b381-00f4e363b24d
Arbizu, J. (Javier)|||/items/41665d76-74c1-4652-acb9-a98cba4ddd0b
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Amnestic mild cognitive impairment (aMCI)
Alzheimer’s disease (AD)
Short-term conversion
AmyloidPET
FDG-PET
topic Amnestic mild cognitive impairment (aMCI)
Alzheimer’s disease (AD)
Short-term conversion
AmyloidPET
FDG-PET
description Purpose Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer’s disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and FDG-PET in determining progression to AD among patients with aMCI. Methods This study recruited 145 patients with aMCI from October 2013 to March 2021. The patients were classified into four groups based on whether Amyloid-PET (A) and FDG-PET (N) were positive (+) or negative (-). The patients were then clinically followed to establish progression to dementia due to AD. Results Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased. The conversion from aMCI to AD had a global mean time of 39.95 months. However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54–81] vs. 32.59 months [CI 20.56–40.74] months). Taking both tests together, the time to conversion was faster in A+/N+versus A+/N- patients (27.79 [CI 20.40–33.21] vs. 37.38 [CI 20.73–48.26] months). Conclusions Among patients with aMCI, those with a positive Amyloid-PET and an AD pattern on FDG-PET progressed to dementia significantly earlier versus those with a positive Amyloid-PET only. Using both biomarkers during the initial diagnosis enhances the prediction of short-term conversion. Clinical trial number Not applicable. It is not a clinical trial
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-01-01
2025
2025-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/120959
url https://hdl.handle.net/10171/120959
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409862925942784
score 15,811543

Similares en LA Referencia